Benjamin R. Puliafito

Hematology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.

Journal: International journal of hematology

Published: April 14, 2026

Choosing the optimal maintenance strategy in multiple myeloma.

Choosing the optimal maintenance strategy in multiple myeloma.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Journal: Blood

Published: November 07, 2025

Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.

Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.

Journal: Blood

Published: November 07, 2025

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

Journal: Blood cancer journal

Published: October 19, 2025

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.

Journal: Leukemia

Published: July 17, 2025

Bispecific T-cell engager therapy for multiple myeloma.

Bispecific T-cell engager therapy for multiple myeloma.

Journal: Best practice & research. Clinical haematology

Published: June 03, 2025

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.

Journal: Blood advances

Published: March 13, 2025

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.

Journal: Blood

Published: December 20, 2024

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

Journal: Leukemia

Published: November 05, 2024

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 31, 2023

Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.

Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.

Journal: Nature biotechnology

Published: August 23, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026